Roberto Calle

, United States


Presentations

Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with nonalcoholic fatty liver disease 12 April 2019 17:15 - 17:30

Abstracts

Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with nonalcoholic fatty liver disease NAFLD: Therapy More